Related Experiment Video
Updated: Sep 15, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Moving cellular therapies to the front line for Ph+ B cell acute lymphoblastic leukemia
Yanzhi Feng1, Etienne Leveille1, Jae H Park2
1Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.
Abstract:
Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph+ B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability.1.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)